Ondine Biomedical Inc
LSE:OBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (34), the stock would be worth GBX2.57 (79% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 165 | GBX12.5 |
0%
|
| 3-Year Average | 34 | GBX2.57 |
-79%
|
| 5-Year Average | 19.1 | GBX1.45 |
-88%
|
| Industry Average | 3.3 | GBX0.25 |
-98%
|
| Country Average | 2.7 | GBX0.2 |
-98%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
O
|
Ondine Biomedical Inc
LSE:OBI
|
64.8m GBP | 165 | -5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 9.5 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 3.1 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 5.6 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 2.2 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 4 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 2.2 | 19.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 4.5 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 27.9 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 1.7 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.9B USD | 3.1 | 15.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
